General Information of This Antibody
Antibody ID
ANI0VLZLL
Antibody Name
Fv-LDP-D3
Synonyms
Cetuximab Fv+the apoprotein of lidamycin+the third domain of human serum albumin
   Click to Show/Hide
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Humanized IgG1-kappa
Antigen Name
Epidermal growth factor receptor (EGFR)
 Antigen Info 
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Fv-LDP-D3-AE [Investigative]
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 64.00% (Day 28) High EGFR expression (EGFR+++)
Method Description
KYSE150 cells (5 10 6 cells/200 L) suspended in PBS were inoculated subcutaneously into the right armpit of athymic mice. When the tumor volume reached about 80mm3, nude mice were randomized into two groups (n=6, per group), a control group and a Fv-LDP-D3-AE (0.2 mg/kg) group. The drug treatment group was given by tail vein injection once a week for two consecutive weeks.

   Click to Show/Hide
In Vivo Model Esophageal squamous cell carcinoma CDX model
In Vitro Model Esophageal squamous cell carcinoma KYSE-150 cells CVCL_1348
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 73.00% (Day 28) High EGFR expression (EGFR+++)
Method Description
KYSE150 cells (5 10 6 cells/200 L) suspended in PBS were inoculated subcutaneously into the right armpit of athymic mice. When the tumor volume reached about 80mm3, nude mice were randomized into two groups (n=6, per group), a control group and a Fv-LDP-D3-AE (0.25 mg/kg) group. The drug treatment group was given by tail vein injection once a week for two consecutive weeks.

   Click to Show/Hide
In Vivo Model Esophageal squamous cell carcinoma CDX model
In Vitro Model Esophageal squamous cell carcinoma KYSE-150 cells CVCL_1348
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 81.00% (Day 28) High EGFR expression (EGFR+++)
Method Description
KYSE150 cells (5 10 6 cells/200 L) suspended in PBS were inoculated subcutaneously into the right armpit of athymic mice. When the tumor volume reached about 80mm3, nude mice were randomized into two groups (n=6, per group), a control group and a Fv-LDP-D3-AE (0.5 mg/kg) group. The drug treatment group was given by tail vein injection once a week for two consecutive weeks.

   Click to Show/Hide
In Vivo Model Esophageal squamous cell carcinoma CDX model
In Vitro Model Esophageal squamous cell carcinoma KYSE-150 cells CVCL_1348
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
33.00 ng/mL
High EGFR expression (EGFR+++)
Method Description
The CCK8 method was used to evaluate the cytotoxicity of Fv-LDP-D3 and Fv-LDP-D3-AE in KYSE150, KYSE520, and Eca109 cells.
In Vitro Model Esophageal squamous cell carcinoma KYSE-150 cells CVCL_1348
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
44.00 ng/mL
High EGFR expression (EGFR+++)
Method Description
The CCK8 method was used to evaluate the cytotoxicity of Fv-LDP-D3 and Fv-LDP-D3-AE in KYSE150, KYSE520, and Eca109 cells.
In Vitro Model Esophageal squamous cell carcinoma KYSE-520 cells CVCL_1355
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
75.00 ng/mL
Moderate EGFR expression (EGFR++)
Method Description
The CCK8 method was used to evaluate the cytotoxicity of Fv-LDP-D3 and Fv-LDP-D3-AE in KYSE150, KYSE520, and Eca109 cells.
In Vitro Model Esophageal squamous cell carcinoma Eca-109 cells CVCL_6898
References
Ref 1 A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer. Drug Deliv. 2022 Dec;29(1):1243-1256.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.